Pipeline for chronic rhinosinusitis

Product
Candidate

Preclinical

Phase 1

Phase 2

Phase 3
LYR-210
Long-acting Mometasone Furoate
Chronic Rhinosinusitis - Patients with Surgically Naïve* Anatomy
 
ENLIGHTEN
Program Ongoing
LYR-220
Long-acting Mometasone Furoate
Chronic Rhinosinusitis - Patients with Post-Surgical Anatomy
 
BEACON
Trial Ongoing
*surgically naïve ethmoid sinuses

 

At Lyra Therapeutics, our focus is chronic rhinosinusitis (CRS). We are leveraging our innovative technology to develop new treatments for this challenging disease that impacts daily life for millions of people.

Lyra Therapeutics’ product candidates are designed to provide medicine directly to sinonasal tissues that are not accessible with conventional therapeutic approaches. Our lead product candidate, LYR-210, is in Phase 3 trials for CRS patients with surgically naïve anatomy. Our second product candidate, LYR-220, is in Phase 2 trials for CRS patients with post-surgical anatomy.

Back to Top